Clinical TrialsObsidian’s Amsoki-cel Shows 67% ORR in ICI-Resistant Melanoma Obsidian’s Amsoki-cel Shows 67% ORR in ICI-Resistant Melanoma Read Post »
Clinical TrialsGilead Reports 75.4% ALP Normalization With Livdelzi in IDEAL Trial Gilead Reports 75.4% ALP Normalization With Livdelzi in IDEAL Trial Read Post »
Clinical TrialsAkeso Reports Strong Pathological Responses With Ivonescimab in NSCLC Akeso Reports Strong Pathological Responses With Ivonescimab in NSCLC Read Post »
Clinical TrialsBrii Bio Shows Improved HBsAg Loss With BRII-179 Triple Therapy Brii Bio Shows Improved HBsAg Loss With BRII-179 Triple Therapy Read Post »
Clinical TrialsIpsen Reports 85.3% ALP Normalization With IQIRVO in PBC Ipsen Reports 85.3% ALP Normalization With IQIRVO in PBC Read Post »
Clinical TrialsZai Lab Reports Broad Tumour Responses With Zocilurtatug in epNEC Zai Lab Reports Broad Tumour Responses With Zocilurtatug in epNEC Read Post »
Clinical TrialsCaldera Reports CLD-423 Data, Expands Pipeline Through Qyuns Deal Caldera Reports CLD-423 Data, Expands Pipeline Through Qyuns Deal Read Post »
Clinical TrialsAmgen Links Repatha to 20% Lower Heart Attack Rate Than Ezetimibe Amgen Links Repatha to 20% Lower Heart Attack Rate Than Ezetimibe Read Post »
Clinical TrialsIksuda Reports 53% Response Rate for IKS03 in B-Cell Lymphoma Iksuda Reports 53% Response Rate for IKS03 in B-Cell Lymphoma Read Post »
Clinical TrialsCitius Reports LYMPHIR Quality-of-Life Improvements in CTCL Citius Reports LYMPHIR Quality-of-Life Improvements in CTCL Read Post »
Clinical TrialsSELLAS Reports 57% Response Rate with SLS009 in TP53-Mutated AML SELLAS Reports 57% Response Rate with SLS009 in TP53-Mutated AML Read Post »
Clinical TrialsMenarini Reports Dapolsertib Activity in Heavily Pretreated B-Cell Lymphoma... Menarini Reports Dapolsertib Activity in Heavily Pretreated B-Cell Lymphoma... Read Post »
Clinical TrialsTaiho’s ASTX030 Meets Phase 3 Endpoint in MDS and CMML Taiho’s ASTX030 Meets Phase 3 Endpoint in MDS and CMML Read Post »
Clinical TrialsADC Highlights Strong ZYNLONTA Responses Across Three Trials ADC Highlights Strong ZYNLONTA Responses Across Three Trials Read Post »
Clinical TrialsSanofi Terminates Nurix’s Oral STAT6 Degrader Programme Sanofi Terminates Nurix’s Oral STAT6 Degrader Programme Read Post »
Clinical TrialsPfizer Ends Development of Three Candidates in ITP, PAH and Obesity Pfizer Ends Development of Three Candidates in ITP, PAH and Obesity Read Post »
Clinical TrialsHoth Ends HT-001 Phase 2a Early, Plans FDA Talks on Potential Phase 3 Hoth Ends HT-001 Phase 2a Early, Plans FDA Talks on Potential Phase 3 Read Post »
Clinical TrialsSeres Reports 77% Reduction in Bloodstream Infections With SER-155 Seres Reports 77% Reduction in Bloodstream Infections With SER-155 Read Post »
Clinical TrialsMerck Advances Ohtuvayre into Phase 3 COPD Exacerbation Trial Merck Advances Ohtuvayre into Phase 3 COPD Exacerbation Trial Read Post »
Clinical TrialsTiziana Reports Positive Phase 2a Results for Intranasal Foralumab Tiziana Reports Positive Phase 2a Results for Intranasal Foralumab Read Post »
Clinical TrialsGSK Depemokimab Maintains Asthma Control Over Two Years GSK Depemokimab Maintains Asthma Control Over Two Years Read Post »
Clinical TrialsIncyte Reports Positive Results for Povorcitinib in Vitiligo Trials Incyte Reports Positive Results for Povorcitinib in Vitiligo Trials Read Post »
Clinical TrialsAgenus Reports 36% Major Response With BOT+BAL in Colon Cancer Agenus Reports 36% Major Response With BOT+BAL in Colon Cancer Read Post »
Clinical TrialsTeva to Stop TOPAS-MSA Trial After Interim Futility Finding Teva to Stop TOPAS-MSA Trial After Interim Futility Finding Read Post »
Clinical TrialsMilestone Reports 66.7% PSVT Conversion With CARDAMYST After Ablation Milestone Reports 66.7% PSVT Conversion With CARDAMYST After Ablation Read Post »
Clinical TrialsEnlivex Reports 79.2% Allocetra Response in Older Knee OA Patients Enlivex Reports 79.2% Allocetra Response in Older Knee OA Patients Read Post »
Clinical TrialsLilly’s AtaiBeckley Reports Positive Mebufotenin Results in Depressio... Lilly’s AtaiBeckley Reports Positive Mebufotenin Results in Depressio... Read Post »
Clinical TrialsInventisBio’s D-2570 Delivers Up to 90% PASI 75 Response in Psoriasis Tri... InventisBio’s D-2570 Delivers Up to 90% PASI 75 Response in Psoriasis Tri... Read Post »
Clinical TrialsAtom’s Lingdolinurad Delivers Strong Phase 2b Gout Results Atom’s Lingdolinurad Delivers Strong Phase 2b Gout Results Read Post »
Clinical TrialsAbbott Reports Strong TECTONIC Results for SonicForce IVL Abbott Reports Strong TECTONIC Results for SonicForce IVL Read Post »
Clinical TrialsAer Therapeutics Reports Phase 2a Failure for Fexlamose in COPD Aer Therapeutics Reports Phase 2a Failure for Fexlamose in COPD Read Post »
Clinical TrialsRegeneron’s Libtayo Maintains DFS Benefit in Longer-Term C-POST Resul... Regeneron’s Libtayo Maintains DFS Benefit in Longer-Term C-POST Resul... Read Post »
Clinical TrialsSobi Reports Positive REDUCE-2 Results for Pozdeutinurad Sobi Reports Positive REDUCE-2 Results for Pozdeutinurad Read Post »
Clinical TrialsAcumen Reports Sabirnetug Failure Despite Amyloid Reduction Acumen Reports Sabirnetug Failure Despite Amyloid Reduction Read Post »
Clinical TrialsAlnylam’s Brezosiran Lowers Mutant Huntingtin by Up to 64% Alnylam’s Brezosiran Lowers Mutant Huntingtin by Up to 64% Read Post »
Clinical TrialsGeron Discontinues IMpactMF Trial After DMC Flags OS Endpoint Risk Geron Discontinues IMpactMF Trial After DMC Flags OS Endpoint Risk Read Post »
Clinical TrialsOSE’s Tedopi Shows Encouraging Survival Results in NSCLC Trial OSE’s Tedopi Shows Encouraging Survival Results in NSCLC Trial Read Post »
Clinical TrialsaTyr’s Efzofitimod Shows Mixed Results in Sarcoidosis aTyr’s Efzofitimod Shows Mixed Results in Sarcoidosis Read Post »
Clinical TrialsCervoMed Reports Mixed Findings for Neflamapimod in DLB CervoMed Reports Mixed Findings for Neflamapimod in DLB Read Post »
Clinical TrialsAscletis’ Oral ASC30 Delivers Up to 1.7% HbA1c Reduction Ascletis’ Oral ASC30 Delivers Up to 1.7% HbA1c Reduction Read Post »
Clinical TrialsOno Advances ONO-1110 Despite Failed Pain Trial Endpoints Ono Advances ONO-1110 Despite Failed Pain Trial Endpoints Read Post »
Clinical TrialsHUTCHMED’s SAFFRON Shows Benefit from Adding Savolitinib After Osimertini... HUTCHMED’s SAFFRON Shows Benefit from Adding Savolitinib After Osimertini... Read Post »
Clinical TrialsHUTCHMED Reports 24.9-Month PFS With First-Line Savolitinib Combination HUTCHMED Reports 24.9-Month PFS With First-Line Savolitinib Combination Read Post »
Clinical TrialsBioNTech and DualityBio Report Modest PFS Gain but Higher ILD in Breast Can... BioNTech and DualityBio Report Modest PFS Gain but Higher ILD in Breast Can... Read Post »
Clinical TrialsPrilenia Reports Functional and Survival Signals for Pridopidine in ALS Prilenia Reports Functional and Survival Signals for Pridopidine in ALS Read Post »
Clinical TrialsUroGen’s Five-Year Data Support Durable JELMYTO Responses UroGen’s Five-Year Data Support Durable JELMYTO Responses Read Post »
Clinical TrialsRetatrutide Delivers 20.9% Mean Weight Loss Against Semaglutide Retatrutide Delivers 20.9% Mean Weight Loss Against Semaglutide Read Post »
Clinical TrialsLynk Reports Positive 76-Week Zemprocitinib Results in Rheumatoid Arthritis Lynk Reports Positive 76-Week Zemprocitinib Results in Rheumatoid Arthritis Read Post »
Clinical TrialsAmgen Reports Phase 3 Success for Dazodalibep in Sjögren’s Disease Amgen Reports Phase 3 Success for Dazodalibep in Sjögren’s Disease Read Post »
Clinical TrialsGrünenthal Reports Sustained Pain Reduction With Qutenza Grünenthal Reports Sustained Pain Reduction With Qutenza Read Post »